Meiji Seika Pharma Announces that it has entered into an Alliance Agreement for Distribution and Sales of ARCT-154 with CSL Seqirus. Domestic manufacturing system will be promoted by ARCALIS’ mRNA drug manufacturing facility.
Meiji Seika Pharma Co., Ltd. and CSL Seqirus, a subsidiary of CSL Limited (ASX:CSL; USOTC:CSLLY), have entered into a distribution agreement for the distribution and sales of ARCT-154, a next generation mRNA COVID-19 vaccine, in Japan on April 11, 2023. CSL Seqirus has exclusively licensed worldwide rights to the vaccine, ARCT-154, from Arcturus Therapeutics Inc. one of our major shareholders.
Press Release of Meiji Holdings;
https://www.meiji.com/global/news/2023/pdf/230411_01.pdf
ARCALIS is currently building the mRNA drug manufacturing facility in Minamisoma City, Fukushima Prefecture, where we can manufacture ARCT-154 from drug substance to drug product in Japan.